FAS -670A>G Genetic Polymorphism is Associated with Treatment Resistant Depression

Background: Hippocampal neurogenesis has been suggested as a downstream event of antidepressants (AD) mechanism of action and might explain the lag time between AD administration and the therapeutic effect. Despite the widespread use CAD in the context of Major Depressive Disorder (MDD) there are no reliable biomarkers of treatment response phenotypes, and a significant proportion of patients display Treatment Resistant Depression (TRD). Fas/FasL system is one of the best-known death receptor mediated cell signaling systems and is recognized to regulate cell proliferation and tumor cell growth. Recently this pathway has been described to be involved iii neurogenesis and neuroplasticity.Methods: Since FAS -670A> G and FASL -844T> C functional polymorphisms never been evaluated in the context of depression and antidepressant therapy, we genotypecl GAS -670A> G and FASL -844T> C in a subset of 80 MDD patients to evaluate their role in antidepressant treatment response phenotypes.Results: We found that the presence of FAS -670G allele was associated with antidepressant bad prognosis (relapse or TRD: OR=6.200; 95% Cl: [1.875-20.499]; p=0.001), and we observed that patients carrying this allele have a higher risk to develop TRD (OR= 10.895 95% Cl: [1.362-87.135]; p=0.008). Moreover, multivariate analysis adjusted to potentials confounders showed that patients carrying G allele have higher risk of early relapse (HR=3.827; 95% Cl: 11.072-13.6591; p =0.039). FAS mRNA levels were down-regulated among G carriers, whose genotypes were more common in TRD patients. No association was found between FASL-844T > C genetic polymorphism and any treatment phenotypes. Limitations: Small sample size. Patients used antidepressants with different mechanisms of action.Conclusion: To the best of our knowledge this is the first study to evaluate the role of GAS functional polymorphism in the outcome of antidepressant therapy. This preliminary report associates GAS -670A> G genetic polymorphism with Treatment Resistant Depression and with time to relapse. The current results may possibly be given to the recent recognized role of Fas in neurogenesis and/or neuroplasticity.]t.) 2015 Elsevier B.V. All rights reserved.